Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA)
Source: View publication →
In this pivotal Phase III trial, both intravenous and subcutaneous mepolizumab significantly reduced the rate of clinically significant asthma exacerbations in patients with severe eosinophilic asthma compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MENSA trial established mepolizumab as a targeted, effective add-on therapy for patients with severe refractory eosinophilic asthma. It validated the subcutaneous route of administration as a viable, effective alternative to the intravenous route, facilitating easier clinical use and supporting the broader move toward personalized, biomarker-driven management of severe asthma.
Historical Context
Prior to the MENSA trial, the DREAM study (Dose Ranging Efficacy and Safety with Mepolizumab) had demonstrated the clinical efficacy of intravenous mepolizumab in reducing exacerbations in patients with severe eosinophilic asthma. MENSA was designed as a pivotal Phase III trial to confirm these findings, bridge efficacy between intravenous and subcutaneous delivery, and secure regulatory approval, marking a major milestone in the development of monoclonal antibody therapies targeting the IL-5 cytokine pathway for severe asthma.
Guided Discussion
High-yield insights from every perspective
Mepolizumab is a monoclonal antibody that targets Interleukin-5 (IL-5). Based on the pathophysiology of severe asthma, what is the specific role of IL-5 in the inflammatory cascade, and why was the eosinophil count used as the primary biomarker in the MENSA trial?
Key Response
IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils. In the subset of asthma known as 'eosinophilic asthma,' these cells drive airway inflammation and remodeling. The MENSA trial used blood eosinophil counts (≥150 cells/μL at screening or ≥300 cells/μL in the past year) as a surrogate biomarker to identify patients whose asthma is primarily driven by this IL-5-dependent pathway.
A 45-year-old patient with severe asthma experiences three exacerbations per year despite adherence to high-dose ICS-LABA. If their blood eosinophil count is 200 cells/μL, what specific clinical outcome demonstrated in the MENSA trial would justify adding mepolizumab to their regimen?
Key Response
The MENSA trial showed that mepolizumab (both IV and SC) reduced the rate of clinically significant asthma exacerbations by approximately 50% compared to placebo. It also showed significant improvements in the ACQ-5 (Asthma Control Questionnaire) scores and FEV1, providing a multi-faceted benefit for patients who remain uncontrolled on standard-of-care therapy.
The MENSA trial evaluated both intravenous (75mg) and subcutaneous (100mg) mepolizumab. Discuss the clinical implications of the finding that both routes yielded nearly identical reductions in exacerbation rates (~47% vs. 53%), particularly regarding the pharmacodynamics of IL-5 inhibition.
Key Response
The nearly identical efficacy suggests a 'ceiling effect' where the 100mg SC dose provides sufficient systemic exposure to maximally suppress IL-5 activity. For subspecialists, this indicates that while eosinophil suppression is dose-dependent at lower levels, the clinical benefit (exacerbation reduction) stabilizes once a threshold of IL-5 neutralization is reached, supporting the move toward the more convenient SC administration in clinical practice.
The MENSA trial demonstrated a significant reduction in exacerbations, yet many patients in the treatment arm continued to have some symptoms and a subset still experienced exacerbations. How should these findings shape our expectations and the 'treat-to-target' conversation with patients regarding asthma remission versus asthma control?
Key Response
While MENSA is a landmark trial for biologic efficacy, it highlights that anti-IL-5 therapy is not a 'cure.' It successfully addresses the eosinophilic component of the disease (reducing exacerbations), but it may not fully mitigate symptoms driven by airway hyperresponsiveness or non-eosinophilic pathways. This teaches us to use mepolizumab specifically to target the 'exacerbator' phenotype while maintaining other therapies to manage daily symptom burdens.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of the 'blood eosinophil count' as the primary inclusion criterion in MENSA. How might the inclusion of patients based on a single historical value (≥300 cells/μL in the past 12 months) vs. a current value (≥150 cells/μL) introduce phenotypical instability or regression to the mean in the trial results?
Key Response
Eosinophil counts can be highly labile and are suppressed by systemic corticosteroids, which many of these patients take for exacerbations. By allowing a historical high, the researchers ensured they captured patients with the 'potential' for eosinophilic inflammation. However, this risks including patients whose current symptoms might be driven by non-eosinophilic mechanisms, potentially diluting the observed effect size. Researchers must account for this 'phenotype switching' when analyzing longitudinal response to biologics.
The MENSA trial reported a significant reduction in exacerbations, but the placebo group also experienced a lower rate of exacerbations than seen in earlier mepolizumab studies (DREAM trial). As a reviewer, what factors in the study design or patient selection would you flag as potential causes for this improved placebo performance, and does it threaten the study's internal validity?
Key Response
A common 'trial effect' occurs where rigorous monitoring and improved adherence to background ICS/LABA in the placebo arm reduce exacerbation rates. Furthermore, MENSA excluded patients with very frequent recently-treated exacerbations or unstable dosing. While this might reduce the absolute difference between groups, the fact that mepolizumab still achieved a ~50% relative reduction despite an optimized placebo group actually strengthens the argument for its efficacy.
Based on the MENSA trial results, should mepolizumab be prioritized over other biologics (like omalizumab) for patients who qualify for both? How do these findings influence the GINA Step 5 recommendations for the management of difficult-to-treat and severe asthma?
Key Response
MENSA provided high-quality (Level A) evidence that led to the inclusion of anti-IL-5 therapies in GINA Step 5 for patients with a severe eosinophilic phenotype. While GINA does not explicitly prioritize one biologic over another, MENSA (along with the SIRIUS trial) suggests that in patients with high exacerbation rates and clear eosinophilia, mepolizumab offers a more direct mechanistic intervention than anti-IgE, particularly if the patient's IgE levels are low or if they lack a clear allergic trigger.
Clinical Landscape
Noteworthy Related Trials
DREAM Trial
Tested
Mepolizumab (75, 250, or 750 mg IV)
Population
Patients with uncontrolled severe asthma
Comparator
Placebo
Endpoint
Rate of clinically significant asthma exacerbations
SIROCCO Trial
Tested
Benralizumab (30 mg SC every 4 or 8 weeks)
Population
Patients with severe, uncontrolled asthma with eosinophilic phenotype
Comparator
Placebo
Endpoint
Annual exacerbation rate
LIBERTY ASTHMA QUEST Trial
Tested
Dupilumab (200 or 300 mg SC)
Population
Patients with uncontrolled, moderate-to-severe asthma
Comparator
Placebo
Endpoint
Annualized rate of severe asthma exacerbations and FEV1 change
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis